Ozmosi | APL-1706 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

APL-1706

Alternative Names: APL-1706, APL1706, Hexvix, APL 1706
Clinical Status: Active
Latest Update: 2025-10-15
Latest Update Note: News Article

Product Description

Mechanisms of Action: Imaging Agent

Novel Mechanism: No

Modality: Diagnostic Agent

Route of Administration: Topical

FDA Designation: Fast Track - *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Photocure
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for APL-1706

Countries in Clinic: China

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Bladder Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05600322

PC B309/21 / YHCT-HEX-B1

P3

Completed

Bladder Cancer

2023-07-12

25%

2023-11-19

Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status